WhiteHawk Minerals Corp. Announces Second Quarter 2026 Earnings Conference Call for August 13, 2026
Get Alerts WHK Hot Sheet
Join SI Premium – FREE
PHILADELPHIA--(BUSINESS WIRE)-- WhiteHawk Minerals Corp. (NYSE: WHK) (“WhiteHawk Minerals” or the “Company”), a leading natural gas mineral and royalty business in the United States, today announced that it has scheduled its second quarter 2026 earnings conference call and webcast for Thursday, August 13, 2026 at 9:00 AM ET. During the call, WhiteHawk Minerals management will discuss the unaudited financial and operational results for the quarter ended June 30, 2026, followed by a question-and-answer session.
WhiteHawk Minerals will release its second quarter results after the market closes on August 12, 2026. A copy of the earnings release will be available on the Company's Investor Relations website at https://investors.whitehawkminerals.com.
The Company will host a conference call and live webcast on August 13, 2026 at 9:00 AM ET to discuss these results.
Conference Call Details:
Webcast: LINK
Participant Dial-In:
- International: +1 585-542-9983
- US Toll-Free: +1 833-461-5787
- Meeting ID: 423 778 885
An archived replay of the call will be available on the Investors section of WhiteHawk Minerals' website at https://investors.whitehawkminerals.com.
About WhiteHawk Minerals
WhiteHawk Minerals is focused on acquiring and managing high-quality natural gas mineral and royalty interests in premier U.S. basins, with a portfolio concentrated in the Appalachian and Haynesville Basins. As of March 31, 2026, the Company’s portfolio spanned approximately 3.4 million gross DSU acres.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260714995096/en/
Investor and Media:
John Ragozzino Jr., CFA
[email protected]
Source: WhiteHawk Minerals
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alzheon Announces Peer-Reviewed Publication Showing Oral Valiltramiprosate/ALZ-801 Achieves Sustained Plasma Biomarker Reductions Linked to Better Cognitive, Functional, and Brain Atrophy Outcomes in
- The Eye Drink will be placed in Keg N Bottle stores, Expanding Retail Presence Across San Diego
- OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share